Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

Helene Pere; Corinne Tanchot; Jagadeesh Bayry; Magali Terme; Julien Taieb; Cecile Badoual; Olivier Adotevi; Nathalie Merillon; Elie Marcheteau; Véronique Quillien; Claire Banissi; Alain Carpentier; Federico Sandoval; Mevyn Nizard; Françoise Quintin-Colonna; Guido Kroemer; Wolf H. Fridman; Laurence Zitvogel; Stéphane Oudard; Eric Tartour

doi:10.4161/onci.18852

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

Helene Pere, Corinne Tanchot, Jagadeesh Bayry, Magali Terme, Julien Taieb, Cecile Badoual, Olivier Adotevi, Nathalie Merillon, Elie Marcheteau, Véronique Quillien, Claire Banissi, Alain Carpentier, Federico Sandoval, Mevyn Nizard, Françoise Quintin-Colonna, Guido Kroemer, Wolf H. Fridman, Laurence Zitvogel, Stéphane Oudard, Eric Tartour

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

96 Citations (Scopus)

Résumé

CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.

langue originale	Anglais
Pages (de - à)	326-333
Nombre de pages	8
journal	OncoImmunology
Volume	1
Numéro de publication	3
Les DOIs	https://doi.org/10.4161/onci.18852
état	Publié - 2 nov. 2012

Accès au document

10.4161/onci.18852

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Pere, H., Tanchot, C., Bayry, J., Terme, M., Taieb, J., Badoual, C., Adotevi, O., Merillon, N., Marcheteau, E., Quillien, V., Banissi, C., Carpentier, A., Sandoval, F., Nizard, M., Quintin-Colonna, F., Kroemer, G., Fridman, W. H., Zitvogel, L., Oudard, S., & Tartour, E. (2012). Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology, 1(3), 326-333. https://doi.org/10.4161/onci.18852

@article{0ff622eca3e14a649cfc3014a98bc45c,

title = "Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer",

abstract = "CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.",

keywords = "Antiangiogenic molecule, CCR4, Chemokine, Regulatory T cell",

author = "Helene Pere and Corinne Tanchot and Jagadeesh Bayry and Magali Terme and Julien Taieb and Cecile Badoual and Olivier Adotevi and Nathalie Merillon and Elie Marcheteau and V{\'e}ronique Quillien and Claire Banissi and Alain Carpentier and Federico Sandoval and Mevyn Nizard and Fran{\c c}oise Quintin-Colonna and Guido Kroemer and Fridman, {Wolf H.} and Laurence Zitvogel and St{\'e}phane Oudard and Eric Tartour",

note = "Funding Information: This work was supported by Canceropole Ile de France, ANR (Agence Nationale de la Recherche), Ligue contre le Cancer, Association pour la Recherche sur le Cancer, Institut National du Cancer, Centre d{\textquoteright}investigation Clinique en Bioth{\'e}rapie (CIC-BT505), and the Labex Immuno-Oncology.",

year = "2012",

month = nov,

day = "2",

doi = "10.4161/onci.18852",

language = "English",

volume = "1",

pages = "326--333",

journal = "OncoImmunology",

issn = "2162-4011",

number = "3",

}

Pere, H, Tanchot, C, Bayry, J, Terme, M, Taieb, J, Badoual, C, Adotevi, O, Merillon, N, Marcheteau, E, Quillien, V, Banissi, C, Carpentier, A, Sandoval, F, Nizard, M, Quintin-Colonna, F, Kroemer, G, Fridman, WH, Zitvogel, L, Oudard, S & Tartour, E 2012, 'Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer', OncoImmunology, VOL. 1, Numéro 3, p. 326-333. https://doi.org/10.4161/onci.18852

TY - JOUR

T1 - Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

AU - Pere, Helene

AU - Tanchot, Corinne

AU - Bayry, Jagadeesh

AU - Terme, Magali

AU - Taieb, Julien

AU - Badoual, Cecile

AU - Adotevi, Olivier

AU - Merillon, Nathalie

AU - Marcheteau, Elie

AU - Quillien, Véronique

AU - Banissi, Claire

AU - Carpentier, Alain

AU - Sandoval, Federico

AU - Nizard, Mevyn

AU - Quintin-Colonna, Françoise

AU - Kroemer, Guido

AU - Fridman, Wolf H.

AU - Zitvogel, Laurence

AU - Oudard, Stéphane

AU - Tartour, Eric

N1 - Funding Information: This work was supported by Canceropole Ile de France, ANR (Agence Nationale de la Recherche), Ligue contre le Cancer, Association pour la Recherche sur le Cancer, Institut National du Cancer, Centre d’investigation Clinique en Biothérapie (CIC-BT505), and the Labex Immuno-Oncology.

PY - 2012/11/2

Y1 - 2012/11/2

N2 - CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.

AB - CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.

KW - Antiangiogenic molecule

KW - CCR4

KW - Chemokine

KW - Regulatory T cell

UR - http://www.scopus.com/inward/record.url?scp=84871719877&partnerID=8YFLogxK

U2 - 10.4161/onci.18852

DO - 10.4161/onci.18852

M3 - Article

AN - SCOPUS:84871719877

SN - 2162-4011

VL - 1

SP - 326

EP - 333

JO - OncoImmunology

JF - OncoImmunology

IS - 3

ER -